OncoMatch/Clinical Trials/NCT07718490
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Is NCT07718490 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Adebrelimab for metastatic colorectal cancer.
Treatment: Adebrelimab — Metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) molecular phenotypes could significantly benefit from immune checkpoint inhibitor therapy, ushering in the MSI era of immunotherapy for colorectal cancer. However, MSI-H/dMMR is present in only 15%-20% of stage II/III and 5% of stage IV colorectal cancer patients, while the vast majority of patients exhibit microsatellite stability (MSS) or proficient mismatch repair (pMMR) types, which are insensitive to immunotherapy. Therefore, how to enhance the efficacy of immunotherapy in the pMMR/MSS population through combination therapy has become a hotspot and challenge in colorectal cancer research.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
MSS/ PMMR-type advanced colorectal cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Demographics
Prior therapy
Cannot have received: systemic anti-tumor therapy
Exception: neoadjuvant/adjuvant therapy allowed if time from last chemotherapy to recurrence or progression is more than 6 months
No prior systemic anti-tumor therapy; patients who have received neoadjuvant/adjuvant therapy are eligible if the time from the last chemotherapy to recurrence or progression is more than 6 months
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.5×10^9/l; platelet count ≥100×10^9/l; hemoglobin ≥9 g/dl; serum albumin ≥2.5 g/dl
Kidney function
serum creatinine ≤1.5 × uln, or creatinine clearance >60 ml/min (calculated by cockcroft-gault formula)
Liver function
total bilirubin ≤1.5 × uln; alt and ast ≤2.5 × uln, or ≤5 × uln in the presence of liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07718490 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-tumor therapy disqualifies patients from enrollment.
Does this trial require MSH6?
Yes, MSH6 wild-type is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages